Ipswich Investment Management Co. Inc. Cuts Position in Johnson & Johnson (NYSE:JNJ)

Ipswich Investment Management Co. Inc. lowered its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 1.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 50,464 shares of the company’s stock after selling 615 shares during the period. Johnson & Johnson makes up about 2.1% of Ipswich Investment Management Co. Inc.’s portfolio, making the stock its 7th largest holding. Ipswich Investment Management Co. Inc.’s holdings in Johnson & Johnson were worth $7,860,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in JNJ. Rather & Kittrell Inc. increased its holdings in Johnson & Johnson by 2.0% in the second quarter. Rather & Kittrell Inc. now owns 2,909 shares of the company’s stock worth $481,000 after purchasing an additional 58 shares in the last quarter. Capital Square LLC increased its stake in shares of Johnson & Johnson by 1.4% in the 2nd quarter. Capital Square LLC now owns 4,245 shares of the company’s stock valued at $703,000 after acquiring an additional 58 shares in the last quarter. Wagner Wealth Management LLC lifted its position in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Wagner Wealth Management LLC now owns 4,543 shares of the company’s stock valued at $752,000 after acquiring an additional 59 shares during the period. Chesapeake Wealth Management boosted its stake in Johnson & Johnson by 0.7% during the second quarter. Chesapeake Wealth Management now owns 9,196 shares of the company’s stock worth $1,522,000 after acquiring an additional 60 shares in the last quarter. Finally, RPG Investment Advisory LLC increased its stake in Johnson & Johnson by 1.2% in the second quarter. RPG Investment Advisory LLC now owns 4,876 shares of the company’s stock valued at $807,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 68.40% of the company’s stock.

Johnson & Johnson Stock Up 0.7 %

Johnson & Johnson stock opened at $157.87 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. The stock has a market cap of $380.04 billion, a PE ratio of 11.43, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $175.97. The firm’s 50-day simple moving average is $158.18 and its 200 day simple moving average is $158.62.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.28 by $0.01. The company had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. Johnson & Johnson’s quarterly revenue was down 9.7% on a year-over-year basis. During the same period in the prior year, the company posted $2.35 earnings per share. Research analysts predict that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th will be paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s payout ratio is 34.47%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on JNJ shares. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $170.00 to $163.00 in a research note on Wednesday, December 13th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Morgan Stanley cut their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 24th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Tuesday, February 6th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $176.14.

Get Our Latest Research Report on Johnson & Johnson

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.20% of the stock is owned by insiders.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.